NASDAQ:BIS
ProShares UltraShort Nasdaq ETF News
$19.94
-0.540 (-2.64%)
At Close: Apr 23, 2024
Best Inverse/Leveraged ETFs of Last Week
09:01am, Monday, 26'th Jun 2023
Wall Street gave a muted performance last week as the S&P 500 and the Nasdaq snapped the prolonged winning streak.
3 ETFs in “Oversold” Territory to Start the Week
01:58pm, Monday, 05'th Dec 2022
Technical analysis can tell investors a lot about both stocks and ETFs, including when some might have been overbought, or even oversold.
2 ETFs to Watch for Outsized Volume on Internet & Inverse Leveraged Biotech
08:17am, Monday, 10'th Oct 2022
Inverse leveraged biotech ETF and internet ETF traded with an outsized volume on Friday.
Purchase Levels Of 31 Short ETFs Signal Bear Market Bottom (Technical Analysis)
06:12pm, Monday, 08'th Aug 2022
We are bearish on all American bear market ETFs. Measuring the purchase levels of short ETFs replaces the old, odd lot and total short selling indicators so popular in the 1960s, 70s and 80s.
Cap-Weighting Crucial When Indexing Biotech
01:53pm, Tuesday, 25'th Jan 2022
The biotechnology industry is a bifurcated space. In one corner, you have nascent, small-cap companies that don't yet have steady revenue streams because their new drug or treatment is still in develo
Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index
04:15pm, Friday, 17'th Dec 2021 Benzinga
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ: CMPS) revealed Friday that it has been selected for addition to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective as o
The biotech sector as a safe bet for investments during the crisis
02:00pm, Monday, 29'th Jun 2020
Biotechnology companies have many growth levers and are to be favored for their defensive qualities, in the context of the health and economic crisis.
Health Care Up On Biotech Demand -- Health Care Roundup | MarketScreener
09:25pm, Thursday, 25'th Jun 2020Health Care Down, But Not By Much, Amid Defensive Bias -- Health Care Roundup
09:02pm, Wednesday, 24'th Jun 20202 Biotech Stocks With Major Incoming Catalysts | The Motley Fool
10:49am, Wednesday, 24'th Jun 2020
While everyone's focused on COVID-19, these drugmakers are looking forward to unrelated FDA approvals that could push their stock prices into the clouds.
ING's Latest Economic Views And Forecasts
07:52pm, Monday, 16'th Mar 2020
Our gut feeling is that this will not be the last update. US: We are penciling in an 8.0% annualised 2Q20 GDP decline. Europe: Bund yields will likely continue
Dems attack Trump over stalled efforts to lower drug prices
02:32pm, Friday, 21'st Feb 2020
High drug prices will, again, be a key issue in the 2020 Presidential campaign considering that President Trump has made scant progress on the matter despite much rhetoric.White House press secretary
Review Of The Current Investment Landscape - 2019 Edition
06:27am, Wednesday, 22'nd Jan 2020
Following a difficult end to 2018, equity markets delivered very strong returns in 2019. Remarkably, traditional ‘risk-off’ assets such as bonds and precious me
Drugmakers getting creative over ways to pay for pricey meds
05:16pm, Monday, 13'th Jan 2020
Faced with pushback from multiple fronts over high drug prices, biopharmaceutical firms are experimenting with new ways to get paid for their priciest offerings, mostly biologics, in a report from the
California mulling private-label generics to address high drug costs
03:05pm, Thursday, 09'th Jan 2020
The new budget proposed by California Governor Gavin Newsom includes a plan to allow the state to contract with generic drug makers to provide medicines to all Californians. He believes that the gover
